Related Experiment Videos
Spasmocanulase in irritable bowel syndrome
Abdelrahman E Mohamed1, Zuhal M Ghandour, Mohamed A Al-Karawi
1Department of Gastroenterology, Armed Forces Hospital, PO Box 7897, Riyadh 11159, Kingdom of Saudi Arabia.
Saudi Medical Journal
|October 9, 2002
Summary
Spasmocanulase effectively improved symptoms in over 50% of irritable bowel syndrome patients unresponsive to prior treatments. This study suggests spasmocanulase is a beneficial option for managing functional gastrointestinal disorder symptoms.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder with complex symptomatology.
- Effective management of IBS remains challenging, with many patients unresponsive to existing pharmacotherapies.
Purpose of the Study:
- To evaluate the efficacy of Spasmocanulase in patients with IBS who previously failed other treatments.
- To assess the impact of Spasmocanulase on key IBS symptoms including abdominal pain, bloating, flatulence, diarrhea, and constipation.
Main Methods:
- A study involving 21 IBS patients with a history of treatment failure for over two years.
- Patients received Spasmocanulase (one tablet three times daily) for six months, with follow-ups every six weeks.
- Previous medications were discontinued, and symptom changes were monitored.
Main Results:
- Over 50% of patients experienced symptom improvement or resolution.
- Overall symptom improvement ranged from 43-75% at 6 weeks and 3 months.
- Spasmocanulase demonstrated significant improvement in abdominal pain, flatulence, and bloating compared to prior medications; 43% of patients with diarrhea showed improvement.
Conclusions:
- Spasmocanulase shows promise as a beneficial treatment for improving symptoms in patients with irritable bowel syndrome.
- Despite a small study cohort, the findings indicate a positive therapeutic effect of Spasmocanulase for IBS management.